Telehealth giant Hims & Hers is the latest — and arguably the biggest — company to step into the surging market for personalized lab testing
Telehealth platform Hims & Hers is expanding into diagnostic testing, introducing a subscription-based service to make preventive lab work more accessible.
Called Labs, the service offers annual or biannual blood tests that measure key health markers such as heart health, metabolism and hormones, along with doctor-developed plans that recommend lifestyle changes or treatment options when appropriate.
The launch comes as consumers face growing cost pressure around basic care. A new West Health–Gallup survey published this week finds that 47% of U.S. adults worry they may not be able to afford needed care in 2026, marking the highest level of concern since the groups began tracking it in 2021. Rising premiums and insurance losses tied to layoffs have also made access less predictable, opening the door for more preventive services to be delivered through consumer-focused platforms rather than traditional providers.
“Truly transformational, preventive care has been out of reach for too many people for too long,” Hims & Hers co-founder and CEO Andrew Dudum said. “We’re changing the status quo by making it simple to understand and act on results that matter for your long-term health.”
Labs offers two plans. The Base tier provides one yearly blood draw and 50 biomarker tests across nine categories for $199 per year. The Advanced tier includes two draws a year, over 120 biomarker tests across 10 categories and costs $499 annually. Both include action plans, with the option to pursue personalized treatment if a provider determines it’s appropriate.
Customers choose a testing plan through the Hims & Hers app and schedule a blood draw at a nearby clinic. When results are ready, the app alerts them and displays their biomarker data and a doctor-developed action plan.
“Lab results are at the center of decision-making in primary care and we’re making them simpler, more personal and more actionable,” Hims & Hers chief medical officer Dr. Pat Carroll said. “Most chronic conditions are entirely preventable, but develop long before symptoms appear.”
Hims & Hers expects to broaden the program over time, with plans for at-home testing devices, additional biomarker tests in areas like bone and brain health and more advanced diagnostics to detect chronic and life-threatening conditions.
The Labs launch follows a period of strong growth for the company. Hims & Hers reported nearly $600 million in third-quarter revenue, up 49% year-over-year. The platform now has almost 2.5 million subscribers, a 21% increase from a year earlier.
Brands Race To Offer Blood Testing
Hims & Hers is among a growing field of companies building consumer diagnostics platforms, including market leader Function Health.
In recent weeks, wearable company Whoop rolled out its own blood testing platform, Advanced Labs, following a partnership with Quest Diagnostics. The service pairs curated blood panels with clinician-reviewed results and ties those metrics back to wearable data. Smart ring maker Ultrahuman has also pushed further into diagnostics, adding a $99 biomarker test.
Levels, the health tech company co-founded by Dr. Casey Means, President Trump’s nominee for U.S. Surgeon General, has made similar moves, adding blood testing with AI insights and dietitian access.
Even outside telehealth and wearables, biomarker testing is expanding.
Endurance events brand Spartan recently partnered with Joi + Blokes to track athlete biomarkers as part of a large-scale endurance study. The trend has also reached boutique fitness. This fall, SoulCycle teamed with health app Superpower to bring biomarker testing into its cycling studio challenge.
